Click on the company or penalty amount for more information on each case. Click on the current parent name to reach the summary page for that parent company.
| Company | Current Parent | Current Parent Industry | Primary Offense Type | Year | Agency | Penalty Amount  |
|---|---|---|---|---|---|---|
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | product safety violation | 2023 | private lawsuit-federal | $8,900,000,000 |
| GlaxoSmithKline Holdings (Americas) | GlaxoSmithKline | pharmaceuticals | tax violations | 2006 | IRS | $3,400,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | product safety violation | 2021 | private lawsuit-federal | $2,500,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Merck & Co., Inc. | Merck | pharmaceuticals | tax violations | 2007 | IRS | $2,300,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | DOJ_CIVIL | $784,600,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | drug or medical equipment safety violation | 2002 | DOJ_CIVIL | $500,000,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | DOJ_CIVIL | $465,000,000 |
| Mylan Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $465,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Novartis Pharmaceuticals | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Indivior Inc. | Indivior PLC | pharmaceuticals | price-fixing or anti-competitive practices | 2024 | private lawsuit-federal | $385,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $371,351,180 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| Pfizer, Inc. | Pfizer | pharmaceuticals | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | fraud | 2005 | USAO | $300,000,000 |
| Dey Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Teva Pharmaceuticals USA, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2023 | DOJ_ANTITRUST | $275,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
| United Therapeutics Corporation | United Therapeutics | pharmaceuticals | False Claims Act and related | 2017 | DOJ_CIVIL | $210,000,000 |
| Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Sandoz Inc. | Sandoz Group | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
| Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
| Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
| Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
| Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2010 | MULTI-AG | $169,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| Par Pharmaceuticals, Inc. | Endo International | pharmaceuticals | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Sandoz Inc. | Sandoz Group | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $150,000,000 |
| TAP Pharmaceutical Products | Takeda Pharmaceutical | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | private lawsuit-federal | $150,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | False Claims Act and related | 2010 | USAO | $149,000,000 |
| Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
| Hoffmann-La Roche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | private lawsuit-federal | $130,000,000 |
| Abbott Laboratories Inc. | AbbVie | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
| Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Cephalon | Teva Pharmaceutical Industries | pharmaceuticals | consumer protection violation | 2016 | MULTI-AG | $125,000,000 |
| King Pharmaceuticals | Pfizer | pharmaceuticals | False Claims Act and related | 2005 | DOJ_CIVIL | $124,000,000 |
| King Pharmaceuticals | Pfizer | pharmaceuticals | False Claims Act and related | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $124,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
| Actavis Mid-Atlantic LLC | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $118,614,000 |
| Mylan Pharmaceuticals and UDL Laboratories | Viatris | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $118,000,000 |
| Mylan Pharmaceuticals, Inc. | Viatris | pharmaceuticals | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $118,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
| Mylan Laboratories et al. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $108,000,000 |
| Novartis Pharmaceuticals Corp. | Novartis | pharmaceuticals | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Indivior Inc. | Indivior PLC | pharmaceuticals | price-fixing or anti-competitive practices | 2023 | MULTI-AG | $102,500,000 |
| Mylan Laboratories, Inc. | Viatris | pharmaceuticals | consumer protection violation | 2000 | FTC | $100,000,000 |
| Astellas Pharma US Inc. | Astellas Pharma | pharmaceuticals | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
| Novartis | Novartis | pharmaceuticals | wage and hour violation | 2012 | private lawsuit-federal | $99,000,000 |
| Aventis Pharmaceutical Inc. | Sanofi | pharmaceuticals | False Claims Act and related | 2009 | DOJ_CIVIL | $95,500,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $90,000,000 |
| Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
| Sandoz Inc. | Sandoz Group | pharmaceuticals | price-fixing or anti-competitive practices | 2020 | private lawsuit-federal | $85,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
| Watson Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $79,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | USAO | $75,000,000 |
| Bristol Myers Squibb Co. | Bristol-Myers Squibb | pharmaceuticals | False Claims Act and related | 2021 | MULTI-AG | $75,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | private lawsuit-federal | $75,000,000 |
| Organon Inc. | Organon & Co. | pharmaceuticals | price-fixing or anti-competitive practices | 2005 | private lawsuit-federal | $75,000,000 |
| Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
| Watson Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | False Claims Act and related | 2011 | MULTI-AG | $70,000,000 |
| GlaxoSmithKline PLC | GlaxoSmithKline | pharmaceuticals | price-fixing or anti-competitive practices | 2007 | private lawsuit-federal | $70,000,000 |
| Taro Pharmaceutical USA Inc. | Sun Pharmaceuticals | pharmaceuticals | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $67,643,000 |
| Mylan Inc. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $65,000,000 |
| CSL Limited | CSL Limited | pharmaceuticals | price-fixing or anti-competitive practices | 2014 | private lawsuit-federal | $64,000,000 |
| Lupin Pharmaceuticals, Inc. | Lupin Limited | pharmaceuticals | False Claims Act and related | 2019 | TX-AG | $63,000,000 |
| Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
| Sanofi Pasteur Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2017 | private lawsuit-federal | $61,500,000 |
| Merck & Co. | Merck | pharmaceuticals | price-fixing or anti-competitive practices | 2017 | private lawsuit-federal | $60,200,000 |
| Johnson & Johnson Vision Care, Inc. | Johnson & Johnson | pharmaceuticals | price-fixing or anti-competitive practices | 2001 | MULTI-AG | $60,000,000 |
| Merck & Co. | Merck | pharmaceuticals | consumer protection violation | 2008 | MULTI-AG | $58,000,000 |
| Mylan Inc. | Viatris | pharmaceuticals | price-fixing or anti-competitive practices | 2012 | private lawsuit-federal | $57,000,000 |
| Pfizer Inc. | Pfizer | pharmaceuticals | drug or medical equipment safety violation | 2012 | FDA | $55,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2003 | MULTI-AG | $55,000,000 |
| Johnson & Johnson Vision Care Inc. | Johnson & Johnson | pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $55,000,000 |
| Schering-Plough Corporation | Merck | pharmaceuticals | price-fixing or anti-competitive practices | 2009 | private lawsuit-federal | $55,000,000 |
| GlaxoSmithKline LLC | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2019 | IL-AG | $54,653,931 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $50,000,000 |
| E. Merck KG | Merck KGaA (EMD) | pharmaceuticals | price-fixing or anti-competitive practices | 2002 | private lawsuit-federal | $50,000,000 |
| Hoechst Marion Roussel, Inc. | Sanofi | pharmaceuticals | price-fixing or anti-competitive practices | 2016 | private lawsuit-state | $50,000,000 |
| Johnson & Johnson | Johnson & Johnson | pharmaceuticals | False Claims Act and related | 2019 | IL-AG | $49,505,368 |
| Pfizer Corporation | Pfizer | pharmaceuticals | False Claims Act and related | 2002 | DOJ_CIVIL | $49,000,000 |
| Hoffman-LaRoche | Roche | pharmaceuticals | price-fixing or anti-competitive practices | 2000 | CA-AG | $47,498,000 |
| SmithKline Beecham | GlaxoSmithKline | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $47,000,000 |
